ClinicalTrials.gg
CompletedNCT01728246Updated Feb 12, 2013Results posted

An Efficacy, Safety and Effects on Quality of Life of Tramadol/Paracetamol as Add-on Therapy in Chronic Osteoarthritis

A Phase 4 interventional study of Tramadol/Paracetamol (APAP) and Non-Tramadol/APAP in Osteoarthritis, sponsored by Janssen Pharmaceutica. Completed at 1 site in Philippines. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-02-12.

Sponsored by Janssen Pharmaceutica (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
473
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing acetaminophen in Osteoarthritis — none open to participants now, none under way, none of them phase 3. Acetaminophen · Osteoarthritis.

Enrollment
3rd of 14
473 · median 79
Started
2007
with 1 other
Phase 4
7 of 14
none open now
Registered
10th of 14
by date
Lead sponsor
1 of 14
Janssen Pharmaceutica

Among the 14 studies testing acetaminophen in Osteoarthritis, this one is the 3rd largest by enrollment, is one of 2 that started in 2007, is one of 7 in phase 4, and was the 10th registered.

Osteoarthritis

2,975 studies on the registry are indexed under Osteoarthritis; 435 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

None of the 14 studies testing acetaminophen in Osteoarthritis is open now. The open studies under Osteoarthritis, anywhere →

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing acetaminophen in Osteoarthritis as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety and effects on Quality of Life (QOL) of tramadol/paracetamol (APAP) as an add-on therapy (medication taken in addition to another medication) in Filipino participants with chronic (lasting a long time) osteoarthritis (disorder, which is seen mostly in older persons, in which the joints become painful and stiff).

Read the detailed description

This is an open-label (all people know the identity of the intervention), randomized (study drug assigned by chance), controlled study to evaluate the efficacy, safety and effects on QOL of tramadol/APAP as an add-on therapy in Filipino participants suffering from chronic pain because of chronic osteoarthritis. Participants will be randomly assigned to 2 groups: tramadol/APAP group and non tramadol/APAP group. Participants in tramadol/APAP group will receive celecoxib 200 milligram (mg) and fixed dose combination of tramadol (37.5 mg)/APAP (325 mg) as add on therapy, while the participants in non-tramadol/APAP group will receive celecoxib 200 mg only. The total duration of the study will be 4 weeks. The participants in both the groups will be given celecoxib 200 mg once daily for 4 weeks. In addition, the participants in the tramadol/APAP group will be given add-on tramadol/APAP doses 3 times a day for 4 weeks. Participants will be asked to return for follow-up at Weeks 2 and 4. Efficacy will be assessed using 100 millimeter (mm) Visual Analog Scale (VAS) while QOL will be assessed using the Oswestry Disability Index (ODI). Participant safety will be monitored throughout the study.

03

Conditions studied

  • Osteoarthritis

Browse trials for

Keywords

  • Osteoarthritis
  • Celecoxib
  • Tramadol
  • Paracetamol
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with chronic osteoarthritis of knee or hip for greater than (>) or equal to (=) 1 year (based on the American College of Rheumatology (ACR) diagnostic criteria for osteoarthritis), who are experiencing at least moderate osteoarthritis pain (>=50 millimeter [mm] in 100 mm Visual Analog Scale [VAS])
  • On any Cyclooxygenase - 2 (COX-2) inhibitors for at least 2 weeks preceding the study
  • Women with must have negative pregnancy test
  • Women of child bearing potential must agree to use accepted methods of
  • Participant has signed the written form

Exclusion criteria

Exclusion Criteria:

  • Participants taking Monoamine oxydase (MAO) inhibitors, neuroleptics or drugs for seizures
  • Severe hepatic impairment (the impaired ability of the liver to fulfill its role in metabolism)
  • On maintenance tramadol and/or paracetamol(APAP)
  • On sedative hypnotics, short-acting analgesics, topical medications and anesthetics, and/or muscle relaxants
  • Pregnant, lactating or breastfeeding participants
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
473 participants (actual)

Study arms

  • Experimental
    Tramadol/Paracetamol (APAP)

    Drug: Tramadol/Paracetamol (APAP)

  • Active comparator
    Non-Tramadol/APAP

    Drug: Non-Tramadol/APAP

Interventions

  • DrugTramadol/Paracetamol (APAP)

    Drug page: Acetaminophen

    Celecoxib 200 milligram (mg) once daily for 4 weeks and fixed dose combination of Tramadol 37.5 mg/Paracetamol 325 mg thrice daily for 4 weeks as add-on therapy.

  • DrugNon-Tramadol/APAP

    Celecoxib 200 mg alone once daily for 4 weeks.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Visual Analogue Scale for Pain (VAS-pain) Score at Week 2

    VAS is a 100 millimeter (mm) scale. Intensity of pain range: 0 mm=no pain to 100 mm=worst possible pain. Change=scores at observation minus score at baseline. An increase in score from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.

    Time frame: Baseline and Week 2

  2. Change From Baseline in VAS-pain Score at Week 4

    VAS is a 100 mm scale. Intensity of pain range: 0 mm=no pain to 100 mm=worst possible pain. Change=scores at observation minus score at Baseline. An increase in score from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.

    Time frame: Baseline and Week 4 Last Observation Carried Forward (LOCF)

  3. Change From Baseline in Oswestry Disability Index (ODI) Score at Week 2

    The ODI is a low back pain-specific, validated instrument that consists of questions related to limitations in performing specific activities of daily living and 1 question related to pain intensity. The ODI is a self-administered questionnaire that is usually completed in less than 5 minutes. The ODI consists of 10 sections. Each section consists of 6 statements ranked from 0 to 5 (0=good to 5=worse). A higher score represents greater disability.

    Time frame: Baseline and Week 2

  4. Change From Baseline in ODI Score at Week 4

    The ODI is a low back pain-specific, validated instrument that consists of questions related to limitations in performing specific activities of daily living and 1 question related to pain intensity. The ODI is a self-administered questionnaire that is usually completed in less than 5 minutes. The ODI consists of 10 sections. Each section consists of 6 statements ranked from 0 to 5 (0=good to 5=worse). A higher score represents greater disability.

    Time frame: Baseline and Week 4 (LOCF)

  5. Percentage of Participants Who Discontinued Because of Rescue Medication

    Rescue medications are medicines that may be administered to the participants when the efficacy of the study drug is not satisfactory, or the effect of the study drug is too great and is likely to cause a hazard to the participant, or to manage an emergency situation.

    Time frame: Baseline up to Week 4

  6. Time to Discontinuation Because of Rescue Medication

    Rescue medications are medicines that may be administered to the participants when the efficacy of the study drug is not satisfactory, or the effect of the study drug is too great and is likely to cause a hazard to the participant, or to manage an emergency situation.

    Time frame: Baseline up to Week 4

07

Results

Posted Jan 14, 2013

Participant flow

Participant flow — Overall Study
MilestoneTramadol/Paracetamol (APAP)Non-Tramadol/APAP
Started242231
Completed206195
Not completed3636
Withdrew: Participant needed rescue medication15
Withdrew: Protocol violation10
Withdrew: Withdrawal by subject23
Withdrew: Lost to follow-up2322
Withdrew: Lack of efficacy11
Withdrew: Adverse event85

Outcome measures

PrimaryChange From Baseline in Visual Analogue Scale for Pain (VAS-pain) Score at Week 2

VAS is a 100 millimeter (mm) scale. Intensity of pain range: 0 mm=no pain to 100 mm=worst possible pain. Change=scores at observation minus score at baseline. An increase in score from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.

Time frame:
Baseline and Week 2
Reported as:
Mean · mm
Change From Baseline in Visual Analogue Scale for Pain (VAS-pain) Score at Week 2
mmTramadol/Paracetamol (APAP)Non-Tramadol/APAP
Baseline71.86 ± 13.48568.03 ± 13.77
Change at Week 2-29.721 ± 16.936-21.972 ± 12.906
Statistical analysis
  • Tramadol/Paracetamol (APAP) vs Non-Tramadol/APAP · t-test, 2 sided · p = <0.05
PrimaryChange From Baseline in VAS-pain Score at Week 4

VAS is a 100 mm scale. Intensity of pain range: 0 mm=no pain to 100 mm=worst possible pain. Change=scores at observation minus score at Baseline. An increase in score from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.

Time frame:
Baseline and Week 4 Last Observation Carried Forward (LOCF)
Reported as:
Mean · mm
Change From Baseline in VAS-pain Score at Week 4
mmTramadol/Paracetamol (APAP)Non-Tramadol/APAP
Change From Baseline in VAS-pain Score at Week 4-45.027 ± 19.963-34.266 ± 15.665
Statistical analysis
  • Tramadol/Paracetamol (APAP) vs Non-Tramadol/APAP · t-test, 2 sided · p = <0.05
PrimaryChange From Baseline in Oswestry Disability Index (ODI) Score at Week 2

The ODI is a low back pain-specific, validated instrument that consists of questions related to limitations in performing specific activities of daily living and 1 question related to pain intensity. The ODI is a self-administered questionnaire that is usually completed in less than 5 minutes. The ODI consists of 10 sections. Each section consists of 6 statements ranked from 0 to 5 (0=good to 5=worse). A higher score represents greater disability.

Time frame:
Baseline and Week 2

No measurements were reported for this outcome.

PrimaryChange From Baseline in ODI Score at Week 4

The ODI is a low back pain-specific, validated instrument that consists of questions related to limitations in performing specific activities of daily living and 1 question related to pain intensity. The ODI is a self-administered questionnaire that is usually completed in less than 5 minutes. The ODI consists of 10 sections. Each section consists of 6 statements ranked from 0 to 5 (0=good to 5=worse). A higher score represents greater disability.

Time frame:
Baseline and Week 4 (LOCF)
Reported as:
Mean · units on a scale
Change From Baseline in ODI Score at Week 4
units on a scaleTramadol/Paracetamol (APAP)Non-Tramadol/APAP
Baseline58.24 ± 17.03457.23 ± 16.780
Change at Week 4 (LOCF)-19.102 ± 15.103-15.177 ± 13.328
Statistical analysis
  • Tramadol/Paracetamol (APAP) vs Non-Tramadol/APAP · t-test, 2 sided · p = <0.05
PrimaryPercentage of Participants Who Discontinued Because of Rescue Medication

Rescue medications are medicines that may be administered to the participants when the efficacy of the study drug is not satisfactory, or the effect of the study drug is too great and is likely to cause a hazard to the participant, or to manage an emergency situation.

Time frame:
Baseline up to Week 4
Reported as:
Number · percentage of participants
Percentage of Participants Who Discontinued Because of Rescue Medication
percentage of participantsTramadol/Paracetamol (APAP)Non-Tramadol/APAP
Percentage of Participants Who Discontinued Because of Rescue Medication0.412.16
PrimaryTime to Discontinuation Because of Rescue Medication

Rescue medications are medicines that may be administered to the participants when the efficacy of the study drug is not satisfactory, or the effect of the study drug is too great and is likely to cause a hazard to the participant, or to manage an emergency situation.

Time frame:
Baseline up to Week 4

No measurements were reported for this outcome.

Adverse events

Collected over From signing of informed consent until 30 days after the last dose of study medication. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tramadol/Paracetamol (APAP)—1/242 (0.4%)19/242 (7.9%)
Non-Tramadol/APAP—1/231 (0.4%)10/231 (4.3%)
Most frequent serious events
Most frequent serious events
EventTramadol/Paracetamol (APAP)Non-Tramadol/APAP
Vaginal BleedingGeneral disorders0/2421/231
Severe HypertensionGeneral disorders1/2420/231
Generalized Body RashesGeneral disorders1/2420/231
Dizziness / NauseaGeneral disorders1/2420/231
Most frequent other events
Showing 10 of 17
Most frequent other events
EventTramadol/Paracetamol (APAP)Non-Tramadol/APAP
Dizziness / NauseaGeneral disorders10/2422/231
DrowsinessGeneral disorders5/2420/231
Abdominal PainGeneral disorders4/2421/231
VertigoGeneral disorders0/2422/231
TachycardiaGeneral disorders0/2421/231
DyspepsiaGeneral disorders0/2421/231
PalpitationGeneral disorders0/2421/231
Leg HeavinessGeneral disorders0/2421/231
HeadacheGeneral disorders0/2421/231
FlatulenceGeneral disorders1/2421/231

Baseline characteristics

Age Continuous
Age Continuous(years)Tramadol/Paracetamol (APAP)Non-Tramadol/APAPTotal
Mean61.991 ± 12.08462.40 ± 12.43762.19 ± 12.248
Sex/Gender, Customized
Sex/Gender, Customized(participants)Tramadol/Paracetamol (APAP)Non-Tramadol/APAPTotal
Female171177348
Male6953122
Unknown213
08

Study locations

1 site
  • Janssen Philippines
    Paranaque City, Metro Manila 1700, Philippines
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2013, 4 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2012
First posted
Nov 19, 2012
Start
Oct 2007
Primary completionActual
May 2008
CompletionActual
May 2008
Results first posted
Jan 14, 2013
Last update
Feb 12, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01728246
Responsible party
Sponsor
First posted
Nov 19, 2012
Start date
Oct 2007
Primary completion
May 2008
Completion
May 2008
Results posted
Jan 14, 2013
Last update
Feb 12, 2013

Study contacts

Janssen Pharmaceutica Clinical trial
study director · Janssen Pharmaceutica

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion